Torasemide

Generic Name: Torasemide

Brand Names: Demadex, Soaanz

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₀N_₄O_₃S

CAS Number: 56211-40-6

Unique Ingredient Identifier: W31X2H97FB

Background: Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.

Indication: Torasemide is indicated for the treatment of edema associated with congestive heart failure, renal or hepatic diseases. From this condition, it has been observed that torasemide is very effective in cases of kidney failure.

As well, torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensives.

Associated Conditions: Edema, Hypertension

Clinical Trials

Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Furosemide
Drug: Torsemide

First Posted Date: 2021-10-26

Last Posted Date: 2024-10-15

Lead Sponsor: Yale University

Target Recruit Count: 47

Registration Number: NCT05093621

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Bioequivalence Study of Two Formulations of Torasemide Tablet 10 mg in Healthy Volunteers Under Fasting Conditions

Phase 1

Completed

Conditions: Bioequivalence

Interventions: Drug: Torasemide tablet 10 mg
Drug: Toradiur® tablet 10 mg

First Posted Date: 2021-06-10

Last Posted Date: 2023-06-29

Lead Sponsor: Pharmtechnology LLC

Target Recruit Count: 26

Registration Number: NCT04921566

Locations: 🇷🇺
Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Yaroslavl", Yaroslavl, Yaroslavl Region, Russian Federation

Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension

Phase 4

Completed

Conditions: Hypertension
Cardiovascular Diseases

Interventions: Drug: Torasemide 5Mg Tablet

First Posted Date: 2017-11-28

Last Posted Date: 2023-09-25

Lead Sponsor: NHS Greater Glasgow and Clyde

Target Recruit Count: 228

Registration Number: NCT03354897

Locations: 🇬🇧
Glasgow Clinical Research Facility, Glasgow, United Kingdom

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Torsemide
Drug: Furosemide

First Posted Date: 2017-09-28

Last Posted Date: 2022-08-19

Lead Sponsor: Duke University

Target Recruit Count: 2859

Registration Number: NCT03296813

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
VA Medical Center/University of Maryland, Baltimore, Maryland, United States
🇺🇸
Drexel University College of Medicine, Philadelphia, Pennsylvania, United States

and more 57 locations

Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects

Phase 1

Completed

Conditions: Congestive Heart Failure
Chronic Kidney Diseases

Interventions: Drug: Demadex 20mg Tablet
Drug: ER Torsemide 20mg Tablet

First Posted Date: 2017-07-12

Last Posted Date: 2018-04-18

Lead Sponsor: Sarfez Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT03214874

Locations: 🇮🇳
I.E.C. Consultants, Bangalore, India

Weight-Based Torsemide Dosing in Subjects With Heart Failure

Phase 4

Completed

Conditions: Heart Failure

Interventions: Other: Standard Outpatient Heart Failure Management
Drug: Torsemide

First Posted Date: 2017-06-15

Last Posted Date: 2022-03-15

Lead Sponsor: New York City Health and Hospitals Corporation

Target Recruit Count: 52

Registration Number: NCT03187509

Locations: 🇺🇸
Jacobi Medical Cent, Bronx, New York, United States

ToRsemide for pOstpartum HYpertension

Phase 2

Completed

Conditions: Preeclampsia

Interventions: Drug: Placebo
Drug: Torsemide

First Posted Date: 2016-06-27

Last Posted Date: 2019-04-10

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 118

Registration Number: NCT02813551

Locations: 🇺🇸
The University of Texas Health Science Center, Houston, Texas, United States

Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics.

Phase 4

Conditions: Arterial Hypertension
Chronic Heart Failure

Interventions: Drug: Torasemide (Diuver)
Drug: Prolonged release Torasemide (Britomar)

First Posted Date: 2014-03-14

Last Posted Date: 2014-03-20

Lead Sponsor: Society of Specialists in Heart Failure

Target Recruit Count: 78

Registration Number: NCT02087332

The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure

Phase 4

Conditions: Heart Failure

Interventions: Drug: Furosemide
Drug: Torasemide

First Posted Date: 2013-09-13

Last Posted Date: 2017-06-08

Lead Sponsor: Medical University of Warsaw

Target Recruit Count: 100

Registration Number: NCT01942109

Locations: 🇵🇱
3rd Clinic of Internal Medicine and Cardiology of Medcial University of Warsaw, Warsaw, Mazowieckie, Poland
🇵🇱
1st Department of Cariology of Medcial University of Warsaw, Warsaw, Mazowieckie, Poland

Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics

Phase 1

Completed

Conditions: Drug Biotransformation
Membrane Transport

Interventions: Drug: Codeine
Drug: Midazolam
Drug: Pravastatin
Drug: Torsemide
Drug: Talinolol
Drug: Caffeine
Drug: Metoprolol

First Posted Date: 2013-05-03

Last Posted Date: 2014-04-21

Lead Sponsor: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

Target Recruit Count: 117

Registration Number: NCT01845194

Locations: 🇩🇪
Dept. of Clinical Pharmacology, Georg-August-University of Goettingen, Goettingen, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy